698387-09-6 | (2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$6.00	$4.00
10mg	98%	in stock	$8.00	$6.00
100mg	98%	in stock	$26.00	$18.00
250mg	98%	in stock	$46.00	$33.00
1g	98%	in stock	$113.00	$79.00
5g	97%	in stock	$542.00	$380.00

Description

• Catalog Number: AB46738
• Chemical Name: (2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
• CAS Number: 698387-09-6
• Molecular Formula: C30H29ClN6O3
• Molecular Weight: 557.0427
• MDL Number: MFCD09752958
• SMILES: CCOc1cc2ncc(c(c2cc1NC(=O)/C=C/CN(C)C)Nc1ccc(c(c1)Cl)OCc1ccccn1)C#N

Computed Properties

• Complexity: 881
• Covalently-Bonded Unit Count: 1
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 40
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 11
• XLogP3: 4.9

Literature

• Adaptive Randomization of Neratinib in Early Breast Cancer.

  The New England journal of medicine 20160707

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Dual blockade of HER2 - twice as good or twice as toxic?

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20121101

• New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

  Cancer treatment reviews 20120801

• Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.

  Biochemical pharmacology 20120801

• Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.

  International journal of cancer 20120701

• A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor.

  Cancer chemotherapy and pharmacology 20120701

• Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.

  Molecular pharmacology 20120701

• Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy.

  International journal of oncology 20120601

• Neratinib (HKI-272) in the treatment of breast cancer.

  Future oncology (London, England) 20120601

• Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study.

  Japanese journal of clinical oncology 20120401

• A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.

  Molecular bioSystems 20120401

• Preformulation stability study of the EGFR inhibitor HKI-272 (Neratinib) and mechanism of degradation.

  Drug development and industrial pharmacy 20120301

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

  Breast (Edinburgh, Scotland) 20111001

• A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments.

  Molecular bioSystems 20110601

• The search for improved systemic therapy of non-small cell lung cancer--what are today's options?

  Lung cancer (Amsterdam, Netherlands) 20110601

• Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.

  British journal of clinical pharmacology 20110401

• Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.

  Journal of medicinal chemistry 20110310

• [Novel target therapies used in breast cancer management].

  Voprosy onkologii 20110101

• Irreversible EGFR inhibitor EKB-569 targets low-LET γ-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma.

  PloS one 20110101

• Reversible covalent binding of neratinib to human serum albumin in vitro.

  Drug metabolism letters 20101201

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100801

• Characterization of HKI-272 covalent binding to human serum albumin.

  Drug metabolism and disposition: the biological fate of chemicals 20100701

• Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620

• The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.

  Cancer investigation 20100501

• Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100310

• [Management of metastatic HER2-positive breast cancer: present and future].

  Bulletin du cancer 20100301

• Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

  Cancer treatment reviews 20091201

• [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.

  Expert opinion on investigational drugs 20091101

• A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090401

• Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20090101

• The development of HKI-272 and related compounds for the treatment of cancer.

  Archiv der Pharmazie 20080801

• Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080601

• The T790M 'gatekeeper' mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.

  Molecular cancer therapeutics 20080401

• Enzyme replacement therapy for Gaucher's disease in patient treated for non-small cell lung cancer.

  Anticancer research 20080101

• HKI-272 in non small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.

  Oncogene 20070726

• Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.

  Cancer cell 20070701

• Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.

  Bioorganic & medicinal chemistry 20070601

• Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.

  Cancer biology & therapy 20070501

• Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

  The oncologist 20070301

• Pharmacology of epidermal growth factor inhibitors.

  The International journal of biological markers 20070101

• Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

  Cancer research 20060701

• The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

  Cancer cell 20060601

• EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.

  Cancer cell 20060601

• Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

  Journal of medicinal chemistry 20050224

• Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.

  Cancer research 20040601